Name | Title | Contact Details |
---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
EHR Software for Behavioral Health Practices. See Why Behavioral Health Professionals Prefer Valant, the Market Leader for EHR.
HSBlox empowers healthcare organizations with the tools and support to manage value-based programs successfully and sustainably. Our platform provides end-to-end administration, simplifies communication between stakeholders, and operationalizes complex contracts for the full range of reimbursement models. Wherever you are on your value-based journey, we`ll meet you there with smart, secure, scalable solutions. Connect with us to learn how.
BillFlash Billing, Payment, Collection, and RCM Services Deliver Great Value to Your Customers Billers Love Easier Bill Processing & Better Payment Results Payers Enjoy Preferred Mobile & Online Billing & Payment Options Resellers Earn New Recurring R...
Mobileum delivers analytics solutions that generate revenues, reduce costs and accelerate digital transformation. Find everything here.